CIK 0001133869 · Non-accelerated filer<br>Smaller reporting company
CAPRICOR THERAPEUTICS, INC.
Sign in to watch- Ticker
- CAPR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (310) 358-3200
- Business address
- 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 97 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-31 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 141,980 | ||
| 2026-03-31 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 | +693 | $1.39 | $963 | 31,240 |
| 2026-03-31 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 | +21,488 | $3.74 | $80K | 52,728 |
| 2026-03-31 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 | +2,819 | $3.18 | $9K | 55,547 |
| 2026-03-31 | Krasney Karen EVP, GENERAL COUNSEL | Sale 10b5-1 | −25,000 | $30.12 | $753K | 30,547 |
| 2026-03-31 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise · Stock Option (Right to Buy) 10b5-1 | −693 | 2,807 | ||
| 2026-03-31 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise · Stock Option (Right to Buy) 10b5-1 | −21,488 | 74,205 | ||
| 2026-03-31 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,819 | 81,261 | ||
| 2026-01-05 | Kelliher Mike Director | Grant or award · Stock Option (Right to Buy) | +15,500 | 15,500 | ||
| 2026-01-05 | Auwaerter Paul Gisbert Director | Grant or award · Stock Option (Right to Buy) | +15,500 | 15,500 | ||
| 2026-01-05 | Auwaerter Paul Gisbert Director | Grant or award · Stock Option (Right to Buy) | +1,360 | 1,360 | ||
| 2026-01-05 | Auwaerter Paul Gisbert Director | Grant or award · Stock Option (Right to Buy) | +5,420 | 5,420 | ||
| 2026-01-05 | Gotwals Philip J Director | Grant or award · Stock Option (Right to Buy) | +15,500 | 15,500 | ||
| 2026-01-05 | Sabar Karimah Es Director | Grant or award · Stock Option (Right to Buy) | +15,500 | 15,500 | ||
| 2026-01-05 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2026-01-05 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2026-01-05 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award · Restricted Stock Units | +2,500 | 2,500 | ||
| 2026-01-05 | Krasney Karen EVP, GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2026-01-05 | Krasney Karen EVP, GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2026-01-05 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 |
Page 3 of 24 · 468 trades